Safety profile of ripretinib, including impact of alopecia, and Palmar-Plantar Erythrodysesthesia Syndrome (PPES) on patient-reported outcomes (PROs), in ≥ fourth-line advanced gastrointestinal stromal tumors (GIST): Analyses from INVICTUS.

Suzanne George,Michael Heinrich,John R. Zalcberg,Sebastian Bauer,Hans Gelderblom,Patrick Schöffski,César Serrano,Robin L. Jones,Steven Attia,Gina Z. DAmato,Ping Chi,Peter Reichardt,Mario E. Lacouture,Elva Cha,Julie Nicole Meade,Rodrigo Ruiz-Soto,Jean-Yves Blay,Margaret von Mehren

Safety profile of ripretinib, including impact of alopecia, and Palmar-Plantar Erythrodysesthesia Syndrome (PPES) on patient-reported outcomes (PROs), in ≥ fourth-line advanced gastrointestinal stromal tumors (GIST): Analyses from INVICTUS.

2020

Suzanne George
Michael Heinrich
John R. Zalcberg
Sebastian Bauer
Hans Gelderblom
Patrick Schöffski
César Serrano
Robin L. Jones
Steven Attia
Gina Z. DAmato
Ping Chi
Peter Reichardt
Mario E. Lacouture
Elva Cha
Julie Nicole Meade
Rodrigo Ruiz-Soto
Jean-Yves Blay
Margaret von Mehren

11539Background: Ripretinib is a novel switch-control TKI that broadly inhibits KIT and PDGFRA kinase signaling. In INVICTUS (NCT03353753), a randomized, double-blind, placebo (PBO)-controlled tria...

Keywords:

Dermatology
GiST
Stromal cell
Pathology
Medicine
safety profile
Palmar-plantar erythrodysesthesia syndrome

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations